癌治療において壊死を標的とするヒト化抗核抗体

Title:

癌治療において壊死を標的とするヒト化抗核抗体

Document Type and Number:

Japanese Patent JP7299209

Kind Code:

B2

Abstract:

Humanized monoclonal anti-nuclear antibodies with enhanced binding affinity and tumor uptake are presented. Particularly preferred antibodies are site-directed mutants of H-CDR3 with up to about 8-fold improvement in affinity as compared to the non-humanized non-mutated form. In further preferred aspects, such humanized antibodies are employed in tumor necrosis targeted delivery of immune modulators, immune effectors, and other therapeutic or diagnostic agents.

More Like This:

JP3868740	New polypeptides and nucleic acids encoding them
WO/2002/012284	IRON REGULATING PROTEIN-2 (IRP-2) AS A DIAGNOSTIC FOR NEURODEGENERATIVE DISEASE
JP2002527055	[Title of Invention] Human ankyrin family protein

Inventors:

Alan, Epstein
Payshen, Fu

Application Number:

JP2020500785A

Publication Date:

June 27, 2023

Filing Date:

March 19, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CANCER THERAPEUTICS LABORATORIES, INC.

International Classes:

C07K16/18; A61K39/395; A61K45/00; A61K45/06; A61K47/68; A61K51/10; A61P35/00; A61P43/00; C07K14/52; C07K19/00; C12N5/09; C12N15/10; C12N15/13; C40B40/08; C40B40/10; G01N33/536

Domestic Patent References:

JP2006517970A
JP2017503511A

Foreign References:

US20160235859

Other References:

Proceedings of the American Association for Cancer Research.,2002年,Vol.43,p.910,#4512
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,1998年,Vol.13, No.4,p.255-268
UPDATE ON CANCER THERAPEUTICS,2006年,Vol.1, No.1,p.33-47

Attorney, Agent or Firm:

Hiroyuki Nagai
Yukitaka Nakamura
Satoru Asakura
Mari Asano
Hiroshi Sorimachi
Hirosuke Endo

Previous Patent: Method and Apparatus for Improving Cell Edge User Performance Via Downlink Coordinated Component Car...

Next Patent: Systems and Mechanisms for Upselling Products in Autonomous Vehicles